ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Molecular Templates Inc

Molecular Templates Inc (MTEM)

1.46
0.04
(2.74%)
Closed October 09 4:00PM
1.46
0.00
( 0.00% )
Pre Market: 4:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

MTEM News

Official News Only

MTEM Discussion

View Posts
Monksdream Monksdream 6 months ago
MTEM under $3
👍️0
Awl416 Awl416 6 months ago
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
👍️0
AJ Freely AJ Freely 1 year ago
$MTEM - Up 12% Pre-Market/ Current Price $0.53
Announces Up to $40 Million Private Placement Offering
👍️0
Ohiostockpicker Ohiostockpicker 1 year ago
Looking good! https://last10k.com/sec-filings/mtem/0001171843-23-003314.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=mtem
👍️0
INFINITI INFINITI 2 years ago
Looks good got a starter $$$$
👍️0
INFINITI INFINITI 2 years ago
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4

Source: GlobeNewswire Inc.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, has received clearance by the United States Food and Drug Administration (“FDA”) following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.
“MT-8421 represents a novel approach to target CTLA-4 in a wholly distinct manner from the current monoclonal antibody approaches. MT-8421 was designed to eliminate CTLA-4-expressing Tregs in the tumor microenvironment (“TME”) through a direct cell-kill mechanism independent of the effector cell presence that antibodies rely upon while not effecting Tregs in the periphery, the major mechanism of antibody-mediated autoimmune toxicity,” said Eric Poma, Chief Executive Officer and Chief Scientific Officer of MTEM.

Preclinical data from MT-8421 showed that in a transgenic mouse model expressing human CTLA-4 and bearing syngeneic subcutaneous tumors, MT-8421 treatment depleted immune suppressive Tregs in the TME but not in the periphery. MT-8421 was well tolerated in a non-human GLP primate toxicology study and achieved serum levels well-above projected IC50 concentrations for Tregs in the TME. MTEM expects to initiate a first-in-human phase I study with MT-8421 by mid-year 2023 at a starting dose of 32 mcg/kg.

About Molecular Templates
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer.

Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates; the prospects of CTLA-4 targeting therapies as a potential treatment; statements relating to the development of MT-8421; the expected timing of initiating and completing enrollment of cohorts and conducting the planned Phase I study of MT-8421; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action for cancer.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process, including the fact that interim results may not be indicative of future results; whether Molecular Templates’ cash resources, will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured, or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contacts:
Dr. Grace Kim
Head of Investor Relations
grace.kim@mtem.com



Primary Logo
👍️0
subslover subslover 2 years ago
Mailbox
Favorites
Level 2


MTEM
Molecular Templates Inc

Molecular Templates Inc (NASDAQ)

Search Symbol or Name

0.815
0.345 (73.40%)
Real-Time
Quote
Board
Chart
Level 2
News
Trades
OptionsNew
Public.com
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
March 09 2023 - 10:02AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, has received clearance by the United States Food and Drug Administration (“FDA”) following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.
“MT-8421 represents a novel approach to target CTLA-4 in a wholly distinct manner from the current monoclonal antibody approaches. MT-8421 was designed to eliminate CTLA-4-expressing Tregs in the tumor microenvironment (“TME”) through a direct cell-kill mechanism independent of the effector cell presence that antibodies rely upon while not effecting Tregs in the periphery, the major mechanism of antibody-mediated autoimmune toxicity,” said Eric Poma, Chief Executive Officer and Chief Scientific Officer of MTEM.

Preclinical data from MT-8421 showed that in a transgenic mouse model expressing human CTLA-4 and bearing syngeneic subcutaneous tumors, MT-8421 treatment depleted immune suppressive Tregs in the TME but not in the periphery. MT-8421 was well tolerated in a non-human GLP primate toxicology study and achieved serum levels well-above projected IC50 concentrations for Tregs in the TME. MTEM expects to initiate a first-in-human phase I study with MT-8421 by mid-year 2023 at a starting dose of 32 mcg/kg.

About Molecular Templates
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer.

Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates; the prospects of CTLA-4 targeting therapies as a potential treatment; statements relating to the development of MT-8421; the expected timing of initiating and completing enrollment of cohorts and conducting the planned Phase I study of MT-8421; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action for cancer.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process, including the fact that interim results may not be indicative of future results; whether Molecular Templates’ cash resources, will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured, or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contacts:
Dr. Grace Kim
Head of Investor Relations
grace.kim@mtem.com



Primary Logo

Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Molecular Templates Charts. Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Molecular Templates Charts.
Latest MTEM Messages
stockguard Thu Sep 26, 2019 3:30 PM (1260 days ago)
Molecular Templates: Pipeline Progressing, Clinical Updates Loom

stockguard Mon Sep 23, 2019 12:03 PM (1263 days ago)
Is Molecular Templates (NASDAQ:MTEM) Using Too Much Debt?

frankmertens Wed Nov 14, 2018 9:57 AM (1576 days ago)
What happened ?

PithicusKong Fri Oct 26, 2018 10:27 AM (1595 days ago)
The latest subscribers at $ 5.50 must not

PithicusKong Sun Sep 23, 2018 12:01 PM (1628 days ago)
A sizable chunk of dilution coming.

ClayTrader Wed Sep 19, 2018 6:50 PM (1632 days ago)
* * $MTEM Video Chart 09-19-18 * *

PithicusKong Wed Sep 19, 2018 9:01 AM (1632 days ago)
Major news...looks like money is going to flow

PithicusKong Sat Sep 8, 2018 9:12 AM (1643 days ago)
I guess not.....

PithicusKong Thu Aug 30, 2018 2:27 PM (1652 days ago)
Looks like this is trending up again.......

PithicusKong Wed Apr 4, 2018 9:58 PM (1800 days ago)
Any opinions on Annual report? Not one post

See More Posts on MTEM Message Board
News
Press Releases
All News
FEATURED Usha Resources Announces Intention to List on the Australian Securities Exchange (ASX)
Thu Mar 09, 2023 1:23 PM (17 hours ago)
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
GlobeNewswire Inc. • Thu Mar 09, 2023 10:02 AM (20 hours ago)
Molecular Templates Announces Participation in Upcoming Conferences
GlobeNewswire Inc. • Wed Mar 01, 2023 4:44 PM (1 week ago)
Statement of Changes in Beneficial Ownership (4)
Edgar (US Regulatory) • Fri Feb 17, 2023 8:01 AM (3 weeks ago)
Statement of Changes in Beneficial Ownership (4)
Edgar (US Regulatory) • Fri Feb 17, 2023 8:01 AM (3 weeks ago)
Statement of Changes in Beneficial Ownership (4)
Edgar (US Regulatory) • Fri Feb 17, 2023 8:01 AM (3 weeks ago)
Amended Statement of Beneficial Ownership (sc 13d/a)
Edgar (US Regulatory) • Tue Feb 14, 2023 4:41 PM (3 weeks ago)
Amended Statement of Ownership (sc 13g/a)
Edgar (US Regulatory) • Tue Feb 14, 2023 4:30 PM (3 weeks ago)
Amended Statement of Ownership (sc 13g/a)
Edgar (US Regulatory) • Tue Feb 14, 2023 6:11 AM (3 weeks ago)
Statement of Ownership (sc 13g)
Edgar (US Regulatory) • Fri Feb 03, 2023 11:59 AM (1 month ago)
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc. • Fri Dec 02, 2022 5:02 PM (3 months ago)
Current Report Filing (8-k)
Edgar (US Regulatory) • Fri Dec 02, 2022 8:03 AM (3 months ago)
More News Articles

Molecular Templates (NASDAQ:MTEM)
Intraday Stock Chart
Friday 10 March 2023 Click Here for more Molecular Templates Charts.
👍️0
stockguard stockguard 5 years ago
Molecular Templates: Pipeline Progressing, Clinical Updates Loom

https://seekingalpha.com/article/4293709-molecular-templates-pipeline-progressing-clinical-updates-loom
👍️0
stockguard stockguard 5 years ago
Is Molecular Templates (NASDAQ:MTEM) Using Too Much Debt?
Simply Wall St.August 29, 2019

https://finance.yahoo.com/news/molecular-templates-nasdaq-mtem-using-113015110.html
👍️0
frankmertens frankmertens 6 years ago
What happened ?
10-q was not that bad after all
👍️0
PithicusKong PithicusKong 6 years ago
The latest subscribers at $ 5.50 must not be very joyous.
👍️0
PithicusKong PithicusKong 6 years ago
A sizable chunk of dilution coming.
👍️0
ClayTrader ClayTrader 6 years ago
* * $MTEM Video Chart 09-19-18 * *

Link to Video - click here to watch the technical chart video

👍️0
PithicusKong PithicusKong 6 years ago
Major news...looks like money is going to flow into MTEM's coffers.
👍️0
PithicusKong PithicusKong 6 years ago
I guess not.....
👍️0
PithicusKong PithicusKong 6 years ago
Looks like this is trending up again.......
👍️0
PithicusKong PithicusKong 7 years ago
Any opinions on Annual report? Not one post in almost a full month.....Hmmmm.
👍️0
PithicusKong PithicusKong 7 years ago
Down somewhat from its recent high.....but holding its present price.
👍️0
PithicusKong PithicusKong 7 years ago
Could be a double whammy here for MTEM....the combination of Bezos, Buffet and the other guy with their revamp of health care, and the plunge in equities primarily caused by computer trading might drop this significantly. I don't know about $4 but then again there is no guarantee when computers are dictating the movement in markets.
👍️0
PithicusKong PithicusKong 7 years ago
So you mean partial bid "lots", because I was under the impression that 100 shares is one bid lot on all exchanges in the US...it's different in other countries.
👍️0
vip1999 vip1999 7 years ago
those could be partial shares... watch the price, especially 4 or 5 digits after the decimal ones. Computer trading uses algorithm that can be funny to watch at times.
👍️0
PithicusKong PithicusKong 7 years ago
True...but I still cannot understand how individual trades can show up with amounts like 2, 8 or 20, and there are lots of them. How does an individual or a broker trade 2 shares?
👍️0
mat23 mat23 7 years ago
Pith, nice consolidation at this level. Lots of good news could be coming over next few months. Been holding since pre merger THLD. Next move up with news could see 15 - 16 range. Low float here !!!
👍️0
PithicusKong PithicusKong 7 years ago
Being pushed down for a reason, or just a general lack of interest because it didn't fly to $ 20.00 Volume is low so it has to be the traders running off to lose their money somewhere else.....like an unemployed doctor......no patience.
👍️0
PithicusKong PithicusKong 7 years ago
Quiet board......doubt that that will happen, but one never knows. Really don't want to see a 'worm" of Wall St start messing with the stock.
👍️0
vip1999 vip1999 7 years ago
it is a good sign that only you and me are posting here. I need it go back to about $4 pre-RS price.
👍️0
PithicusKong PithicusKong 7 years ago
This stock does not need to be "pumped".....I see it is resuming its upward momentum this morning. I have a major distain for pumpers.....worms of the investment community.
👍️0
PithicusKong PithicusKong 7 years ago
It has ben somewhat volatile......at times the price chart looks like a bucksaw blade.
👍️0
vip1999 vip1999 7 years ago
I sure hope so.
👍️0
PithicusKong PithicusKong 7 years ago
Probably because it is not in pennyland......penny flippers and traders stay clear of a stock of this price. Maybe I am wrong but this is more of an investment than a short term fling.
👍️0
vip1999 vip1999 7 years ago
stock went from 7-ish to 12-ish within the last 2 weeks or so and not a single post... hm.....
👍️0
PithicusKong PithicusKong 7 years ago
Update and vision for 2018 from company this AM.
👍️0
jimmy667 jimmy667 7 years ago
TD Waterhouse knew what they were talking about. When a stock moves up like this on no news it usually portends something very positive. When they were still called Threshold it moved up on no news prior to some very promising moves and the merger.
Have been invested in Threshold in past. Looking for another entry.
Go MTEM
👍️0
PithicusKong PithicusKong 7 years ago
Getting beaten up again.......interesting, considering that T.D.Waterhouse has it as a Strong BUY.
👍️0
PithicusKong PithicusKong 7 years ago
Jeez....now I REALLY feel for the buyers above $ 11.00......too much manipulation and robot trading to make this safe yet.
👍️0
PithicusKong PithicusKong 7 years ago
News his AM...concerning first dosing.
👍️0
PithicusKong PithicusKong 7 years ago
Looks like a tug of war going on between the shorts and the believers. Today's chart look like a bucksaw blade.
👍️0
Belladom Belladom 7 years ago
That was a misprint . Meant negative article . I bought more at $8.96 think it pops next week at the conference
👍️0
PithicusKong PithicusKong 7 years ago
Jeeze....I feel for the poor buggers who bought in the $10's and $11's. Too bad the company can't step in and support the stock if it is a shorter.....that could bankrupt the dickhead and put him/her in a shelter house. What did you mean by a "beg" report, or is that just a misprint?
👍️0
Belladom Belladom 7 years ago
No news . Maybe someone is building a short position ahead of a beg report like seeking alpha. Anyway next week is healthcare conference and should see some buying . A couple hundred thousand shares is enough to move this stock up or down a point .
👍️0
PithicusKong PithicusKong 7 years ago
Board is suffering from necrosis.
👍️0
PithicusKong PithicusKong 7 years ago
Interesting sell off.......prying shares out of weak hands or is there a legitimate reason for it! Small volume considering the much higher buying price range in the last week or so.
👍️0
PithicusKong PithicusKong 7 years ago
Well, no complaints today.....hopefully the upward trend will continue. Maybe the rise has scared the shorts out of their "shorts".
👍️0
PithicusKong PithicusKong 7 years ago
What a crock of attempted manipulation ......two pre trades of 100 shares each to pull the price down .33c Are traders that stupid to be sucked in by such B/S?
👍️0
PithicusKong PithicusKong 7 years ago
What is with the movement in this stock....it comes out of the gate with a nice rise and then is immediately pulled back...why would someone sell so much lower than the opening price....as if to cull any upward movement.....is this robot trading, or shorts trying to halt any upward movement?
👍️0
PithicusKong PithicusKong 7 years ago
Looking not so good...falling off a cliff!
👍️0
PithicusKong PithicusKong 7 years ago
Looking good....steady rise.
👍️0
PithicusKong PithicusKong 7 years ago
Looks like it might have......broke through $6.00
👍️0
PithicusKong PithicusKong 7 years ago
Could ringing the closing bell on the Nasdaq exchange today cause an uptick.......maybe. At least it gets the company name into people's vision.
👍️0
suprajzturbo suprajzturbo 7 years ago
Could tomorrow's presentation increase the stock price?
👍️0

Your Recent History

Delayed Upgrade Clock